Abstract
The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension. The study consisted of a 1-year, multicenter, double-blind, parallel-group phase, followed by a 4-year, open-label extension phase. Of the 228 patients enrolled, 100 patients (54/111 doxazosin and 46/117 atenolol) completed the 5-year study. Both treatments were similarly efficacious in controlling blood pressure. As assessed by the Framingham risk equation, which incorporates lipid parameter values, patients receiving doxazosin had significantly less chance of developing coronary heart disease (CHD) within 10 years compared with those patients receiving atenolol (p < 0.05). Doxazosin significantly (p=0.0005) reduced the mean CHD risk from baseline to final visit by 12.3%; whereas, atenolol produced essentially no change in mean risk (0.2% increase). In patients receiving doxazosin, statistically significant (p < 0.05) increases from baseline were observed in serum concentrations of high-density lipoprotein (HDL) cholesterol and the HDL/total cholesterol ratio during the first 2 and 3 years of treatment, respectively. In contrast, significant (p < 0.05) percent redu...Continue Reading
References
Feb 15, 1992·BMJ : British Medical Journal
Jan 1, 1991·American Heart Journal·T TalsethL Daae
May 1, 1989·Hypertension·R H Grimm
Dec 1, 1988·American Heart Journal·T TalsethS Vatle
Jan 15, 1995·Annals of Internal Medicine·B L KasiskeT A Louis
Citations
Feb 8, 2002·Congestive Heart Failure·D A Sica
Feb 20, 2007·Postgraduate Medical Journal·Stephen S Connolly, John M Fitzpatrick
Aug 31, 2007·Drug Development and Industrial Pharmacy·Yoon Hee KwonIn Koo Chun
Feb 7, 2004·Blood Pressure·Aytekin GuvenRamazan Ozdemir
Nov 26, 1999·Clinical and Experimental Hypertension : CHE·T LittlejohnT Marbury
Jan 14, 2010·Current Medical Research and Opinion·Vivian A Fonseca
Dec 7, 2005·The Journal of Clinical Hypertension·Domenic A Sica
Apr 30, 2005·International Journal of Cardiology·Carlos CalvoBeatriz Armada
Mar 30, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pyung Chun OhEak Kyun Shin
Feb 21, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A C PessinaM Muggeo
Feb 8, 2006·Thrombosis Research·Manuel LabiósJusto Aznar
Mar 31, 2015·Open Heart·James J DiNicolantonioJames H O'Keefe
Feb 24, 2001·Journal of the American College of Cardiology·S NavalkarB V Khan
Jun 5, 2002·The Journal of Clinical Hypertension·D A Sica
Jul 21, 2007·Circulation Research·Alan T Remaley
Jun 20, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Paul Ernsberger, Richard J Koletsky
Dec 14, 2006·Clinical Drug Investigation·Giuseppe DerosaRoberto Fogari
Jul 27, 2001·Current Hypertension Reports·D Sica
May 18, 2005·Journal of Cardiovascular Pharmacology·Giuseppe DerosaRoberto Fogari
Jun 15, 2010·Journal of Hypertension·Neil ChapmanBryan Williams
May 28, 2019·The Proceedings of the Nutrition Society·Andrew M Salter
Jul 27, 2000·The British Journal of Nutrition·B A FieldingK N Frayn
Mar 30, 2017·Current Hypertension Reports·Hamish Cg ProsserMarkus P Schlaich
Dec 14, 1999·British Journal of Clinical Pharmacology·M ChungP Meredith